全球Guillain-Barré二氏症候群（GBS）市场规模、份额、趋势和成长分析报告（2026-2034年）

预计Guillain-Barré二氏症候群(GBS) 市场将从 2025 年的 7.9 亿美元成长到 2034 年的 14.1 亿美元，2026 年至 2034 年的复合年增长率为 6.66%。

随着人们对罕见神经系统疾病的认识不断提高以及诊断能力的进步，全球Guillain-Barré二氏症候群（GBS）市场正在成长。Guillain-Barré二氏症候群是严重的自体免疫疾病，会影响週边神经系统，需要及时进行医疗干预。医疗保健支出的增加和神经学研究的进步带来了更有效的治疗方案，从而推动了市场扩张。

格林-巴利症候群（GBS）市场的主要驱动因素包括自体免疫疾病和感染疾病的发生率不断上升，这些疾病和感染都可能导致此症候群。由于医疗基础设施的改善和早期诊断的普及，疾病管理正在不断进步。此外，製药公司和研究机构正在投资临床试验，以开发更有效的治疗方法和辅助疗法，这有望促进整体医疗环境的改善。

未来，随着免疫疗法和个人化医疗的进步，市场预计将持续成长。对罕见疾病研究的日益重视，以及政府对神经系统疾病治疗的支持政策，可望改善患者的治疗效果。随着医疗技术的进步和公众意识的不断提高，Guillain-Barré二氏症候群市场预计将在全球范围内稳步发展。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球Guillain-Barré二氏症候群（GBS）市场：依治疗方法

• 市场分析、洞察与预测
• 静脉注射免疫球蛋白（IVIG）
• 血浆置换疗法
• 其他的

第五章：全球Guillain-Barré二氏症候群（GBS）市场：按类型划分

• 市场分析、洞察与预测
• 急性发炎性去髓鞘化多发性神经病变（AIDP）
• 慢性发炎性去髓鞘化多发性神经根神经病变（CIDP）
• 米勒-费雪症候群（MFS）
• 急性运动轴索性神经病变（AMAN）
• 其他的

第六章 全球Guillain-Barré二氏症候群（GBS）市场：依给药途径划分

• 市场分析、洞察与预测
• 肠外
• 口服

第七章 全球Guillain-Barré二氏症候群（GBS）市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他药房

第八章 全球Guillain-Barré二氏症候群（GBS）市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • Biogen Inc
  • Cadila Healthcare Limited
  • CSL Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Grifols
  • SA
  • LGM Pharma
  • Merck & Co. Inc
  • Octapharma AG
  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited

The Guillain-Barre Syndrome (GBS) Market size is expected to reach USD 1.41 Billion in 2034 from USD 0.79 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Guillain-Barre Syndrome (GBS) Market is growing as awareness of rare neurological disorders increases and diagnostic capabilities improve. Guillain-Barre syndrome is a serious autoimmune condition that affects the peripheral nervous system and requires timely medical intervention. Rising healthcare spending and advancements in neurology research have contributed to the growing availability of effective treatment options, thereby supporting the market's expansion.

Key drivers of the GBS market include the increasing incidence of autoimmune diseases and infections that may trigger the syndrome. Improved healthcare infrastructure and early diagnosis have enabled better disease management. Additionally, pharmaceutical companies and research institutions are investing in clinical trials to develop more effective therapies and supportive treatments, which is expected to boost the overall treatment landscape.

In the future, the market is anticipated to expand with advancements in immunotherapy and personalized medicine. Increasing focus on rare disease research, along with government initiatives supporting neurological disorder treatment, will likely improve patient outcomes. As medical technologies evolve and awareness continues to grow, the Guillain-Barre syndrome market is expected to see steady progress worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange
• Others

By Type

• Acute inflammatory demyelinating polyneuropathy (AIDP)
• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• Miller fisher syndrome (MFS)
• Acute motor axonal neuropathy (AMAN)
• Others

By Route of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Biogen Inc, Cadila Healthcare Limited, CSL Limited, F HoffmannLa Roche Ltd, GlaxoSmithKline plc, Grifols, SA, LGM Pharma, Merck Co Inc, Octapharma AG, Pfizer Inc, Takeda Pharmaceutical Company Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Intravenous Immunoglobulin (IVIG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Plasma Exchange Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Acute inflammatory demyelinating polyneuropathy (AIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Miller fisher syndrome (MFS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Acute motor axonal neuropathy (AMAN) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapeutics
  • 8.2.2 By Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapeutics
  • 8.3.2 By Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapeutics
  • 8.4.2 By Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapeutics
  • 8.5.2 By Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapeutics
  • 8.6.2 By Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Biogen Inc
  • 10.2.3 Cadila Healthcare Limited
  • 10.2.4 CSL Limited
  • 10.2.5 F. Hoffmann-La Roche Ltd
  • 10.2.6 GlaxoSmithKline Plc
  • 10.2.7 Grifols
  • 10.2.8 S.A
  • 10.2.9 LGM Pharma
  • 10.2.10 Merck & Co. Inc
  • 10.2.11 Octapharma AG
  • 10.2.12 Pfizer Inc
  • 10.2.13 Takeda Pharmaceutical Company Limited